Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

New Stem Cell Technique Shows Promise for Bone Repair

By UNIST | January 26, 2017

A recent study, affiliated with UNIST has developed a new method of repairing injured bone using stem cells from human bone marrow and a carbon material with photocatalytic properties, which could lead to powerful treatments for skeletal system injuries, such as fractures or periodontal disease.

This research has been jointly conducted by Professor Youngkyo Seo of Life Sciences and Dr. Jitendra N. Tiwari of Chemistry in collaboration with Professor Kwang S. Kim of Natural Science, Professor Pann-Ghill Suh of Life Sciences, and seven other researchers from UNIST.

In the study, the research team reported that red-light absorbing carbon nitride (C?N?) sheets lead to remarkable proliferation and osteogenic differentiation by runt-related transcription factor 2 (Runx2) activation, a key transcription factor associated with osteoblast differentiation.

The results of the study has been published in the January issue of ACS Nano journal. The research team expects this breakthrough could lead to enhancement of bone regeneration.

The use of human bone marrow-derived mesenchymal stem cells (hBMSCs) has been tried successfully in fracture treatment due to their potential to regenerate bone in patients who have lost large areas of bone from either disease or trauma. Recently, many attempts have been made to enhance the function of stem cells using carbon nanotubes, graphenes, and nano-oxides.

In the study, Professor Kim and Professor Suh examined the C?N?sheets. They discovered that this material absorbs red light and then emits fluorescence, which can be used to speed up bone regeneration. Professor Kim’s team synthesized carbon nitrogen derivatives from melamine compounds. Then, they analyzed the light-absorbing characteristics of C?N?sheets at a wavelength range of 455-635 nanometers (nm). As a result, the C?N?sheets were found to emit fluorescence at the wavelength of 635 nm when exposed to red light in a liquid state. At this time, the released electrons induced calcium to accumulate in the cytoplasm.

Professor Suh conducted a biomedical application of this material. First, stem cells and cancer cells were cultured in a medium containing 200 μg/ml of C?N?sheets. After two days of testing, the material showed no cytotoxicity, making it useful as biomaterials.

It was also confirmed that C?N?sheets act on stem cells to differentiate into osteoblasts to promote mineral formation. In this process, the osteogenic differentiation marker genes (ALP, BSP, and OCN) proliferated. Moreover, the Rux2 (Runt-related transcription factor 2), a key factor in osteoblast differentiation was also activated. This resulted in the increased osteoblast differentiation and accelerated bone formation.

“This research has opened up the possibility of developing a new medicine that effectively treats skeletal injuries, such as fractures and osteoporosis,” said Professor Young-Kyo Seo. “It will be a very useful tool for making artificial joints and teeth with the use of 3D printing.”

He adds, “This is an important milestone in the analysis of biomechanical functions needed for the development of biomaterials, including adjuvants for hard tissues such as damaged bones and teeth.”

The research team expects that their findings affirm the potential of C?N?sheets in developing bone formation and directing hBMSCs toward bone regeneration.


Filed Under: Drug Discovery

 

Related Articles Read More >

Roche in Drug Discovery & Development Pharma 50
Roche’s bispecific antibody Lunsumio wins priority review from FDA for non-Hodgkin lymphoma
Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50